Ashley Gallagher

The drug is approved for the short-term treatment of acute repetitive seizures, also known as seizure clusters, which differ from a patient’s normal seizure pattern.

Thanks to widespread vaccination, the country nearly eliminated measles, maintaining only about 63 cases per year between 2000 and 2019.

The FDA approved adalimumab-aaty in May 2023 for 8 indications, including rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.

One asymptomatic patient did experience drug-induced liver injury that was resolved after discontinuation of danuglipron.

However, patients should still be monitored for potential serious adverse effects, as investigators identified potential new concerns.

Furthermore, C-reactive protein has greater prognosis for lung cancer, colorectal cancer, and ovarian cancer.

The drug is also approved for adults with chronic inflammatory demyelinating polyneuropathy.

The designation addresses the unmet need for prevention of H5N1, which remains a global health risk, and a phase 1 trial of the vaccine was initiated in November 2024.

Pharmacists have positive impacts on health outcomes for diabetes and patients using CGM devices, including reductions in A1c.

Investigators find 5 distinct obesity trajectories that influenced brain morphology, function, and cognition.

Hypertension and obstructive sleep apnea are considered independent risk factors for cardiovascular diseases as well as diabetes.

Jenna Anderson, CEO of KiHealth Inc, and Amanda Wiley, marketing manager of HealthSource Marketing, discuss the evolving role of pharmacies in at-home testing.

Stephanie Downing, MBA, discusses expanding pharmacy services, clinical workflow efficiency, and revenue growth, highlighting the shift from traditional pharmacy roles to providing expanded clinical services.

The drug shows a decrease in proteinuria and is well tolerated and safe, including for Black patients with chronic kidney disease.

Data from the HERCULES phase 3 trial were presented at the 2025 Annual Meeting for the American Academy of Neurology for non-relapsing secondary progressive multiple sclerosis.

Pharmacists are well positioned to screen for diversion, monitor for opioid use disorder, and educate patients on opioid-related risks.

There were no statistically significant differences between cognitive behavioral therapy and mindfulness-based therapy in reducing the dosage for chronic lower back pain.

Further studies are needed to further confirm the association between glucagon-like peptide 1 medication and reductions in dementia risk.

Conflicting study findings show various associations between asthma and COVID-19; further data are needed.

Technology, such as continuous glucose monitors, changes the way patients are treated, but more work needs to be done for racial, ethnic, and socioeconomic disparities.

Texas reports over 480 cases of measles and 2 measles-related deaths, with 1 including an unvaccinated pediatric patient.

Technological evolution promises to enhance patient care, reduce errors, and provide intelligent support that augments human expertise rather than replacing it.

Clinical pharmacists counsel patients during the intervention and make informed medication changes based on the data received from continuous glucose monitoring (CGM).

Pharmacists can also provide education across all pillars of health, including exercise, wellness, and dietary changes.

Pharmacists are transforming health care delivery by breaking down traditional barriers to medication access and patient care.

Experts discuss the evolving landscape of pharmacy through technological advancements, professional development, and advocacy.

Previous research shows herpes zoster is associated with a higher long-term risk of subjective cognitive decline, with increased risk for men who carried APOE ε4.

As over-the-counter birth control becomes increasingly available, pharmacists are uniquely positioned to bridge critical gaps in reproductive health care.

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

Traditional approaches have typically relied on oral medications, which can expose the entire body to potentially harmful adverse effects.